Last close As at 05/08/2026
GBP0.37
▲ −0.30 (−0.80%)
Market capitalisation
GBP111m
Research: Industrials
The acquisition of Harry Peers & Co brings additional expertise to the Severfield portfolio, with particular strengths in relatively robust infrastructure sub-segments. The deal enhances our earnings estimates by over 6% in a full year and raises Severfield’s three-year EPS CAGR to FY22 to just over 8%, and good order book positions provide some comfort given domestic near-term eco-political uncertainties.
Written by
Severfield |
Harry Peers deal enhances earnings |
Acquisition |
Construction & materials |
4 October 2019 |
Share price performance
Business description
Next events
Analyst
Severfield is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
The acquisition of Harry Peers & Co brings additional expertise to the Severfield portfolio, with particular strengths in relatively robust infrastructure sub-segments. The deal enhances our earnings estimates by over 6% in a full year and raises Severfield’s three-year EPS CAGR to FY22 to just over 8%, and good order book positions provide some comfort given domestic near-term eco-political uncertainties.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS** |
P/E |
Yield** |
03/18** |
274.2 |
24.0 |
6.5 |
4.3 |
11.2 |
5.9 |
03/19 |
274.9 |
25.2 |
6.8 |
2.8 |
10.7 |
3.8 |
03/20e |
296.9 |
28.4 |
7.7 |
3.0 |
9.5 |
4.2 |
03/21e |
314.6 |
30.2 |
8.1 |
3.3 |
9.0 |
4.5 |
Note: *PBT and EPS are Edison normalised, excluding pension net finance costs, intangible amortisation and exceptional items. **FY18 DPS included a 1.7p special dividend.
Specialist structural steel supplier
Harry Peers is a well-established, Bolton-based, specialist supplier of structural steelwork to the nuclear, power generation and process industries, each of which has a number of subsectors. Like Severfield, it provides a full design, fabrication and erection service and uses subcontract suppliers to add flexibility to the management of fab capacity, which is understood to be around 4,000 tonnes pa. Peers is understood to have a particular capability in the fabrication of modular structures which facilitate onsite installation. As well as having accreditations in the nuclear and defence sectors, the company’s delivered project portfolio also includes chemicals, petrochemicals, pharmaceuticals plant structures and energy from waste facilities.
Earnings uplift, company retains a net cash position
In the year to April 2019, Harry Peers turned over £21.2m, generating £3.4m PBT. Allowing for some favourable final settlements, normal EBIT margins would appear to be in the low double-digit percentage range. Consideration is an initial £18m net of cash acquired (£30.4m gross) with a potential further £7m deferred, depending on factors including profitability, order book development and other undisclosed qualitative factors. We would expect Severfield to bring steel purchasing synergies to the acquired business, further improving its competitive position, while finance and HR functions will be aligned. For now, our revised estimates point to a c 3.7% enhancement to expected earnings this year and over 6% in the following two years, and we project that Severfield will end FY20 with a c £13m net cash balance, subject to period-end project positions.
Valuation: Favourable response to newsflow
After a share price rally in the last month following the AGM update, Severfield’s P/E and EV/EBITDA are now 9.5x and 6.2x respectively, for FY20 with a prospective dividend yield of 4.2%.
Exhibit 1: Financial summary
£m |
2016 |
2017 |
2018 |
2019 |
2020e |
2021e |
2022e |
||
Year end 31 March |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||||
Revenue |
|
|
239.4 |
262.2 |
274.2 |
274.9 |
296.9 |
314.6 |
318.6 |
Cost of Sales |
(219.6) |
(236.3) |
(244.9) |
(244.6) |
(261.7) |
(277.1) |
(280.2) |
||
Gross Profit |
19.8 |
25.9 |
29.3 |
30.3 |
35.2 |
37.5 |
38.4 |
||
EBITDA |
|
|
18.9 |
25.7 |
29.0 |
29.0 |
33.8 |
36.5 |
37.6 |
Operating Profit - Edison |
|
|
15.2 |
22.1 |
25.4 |
25.4 |
29.5 |
31.5 |
32.2 |
Net Interest |
(0.2) |
(0.2) |
(0.2) |
(0.2) |
(0.3) |
(0.6) |
(0.6) |
||
Associates |
(0.2) |
0.5 |
0.9 |
1.7 |
1.2 |
1.3 |
2.2 |
||
SBP |
(1.1) |
(2.0) |
(2.0) |
(1.6) |
(2.0) |
(2.0) |
(2.0) |
||
Intangible Amortisation |
(2.6) |
(2.6) |
(1.3) |
0.0 |
0.0 |
0.0 |
0.0 |
||
Pension Net Finance Costs |
(0.5) |
(0.5) |
(0.5) |
(0.5) |
(0.5) |
(0.5) |
(0.5) |
||
Exceptionals |
(0.9) |
0.8 |
0.0 |
0.0 |
(0.3) |
0.0 |
0.0 |
||
Profit Before Tax (norm) - Edison |
|
13.7 |
20.3 |
24.0 |
25.2 |
28.4 |
30.2 |
31.8 |
|
Profit Before Tax (norm) |
|
|
13.2 |
19.8 |
23.5 |
24.7 |
27.9 |
29.7 |
31.3 |
Profit Before Tax (statutory) |
|
9.6 |
18.1 |
22.2 |
24.7 |
27.7 |
29.7 |
31.3 |
|
Tax |
(1.0) |
(2.7) |
(4.1) |
(4.5) |
(5.0) |
(5.4) |
(5.5) |
||
Profit After Tax (norm) |
11.4 |
17.0 |
19.5 |
20.7 |
23.4 |
24.8 |
26.3 |
||
Profit After Tax (statutory) |
8.6 |
15.3 |
18.0 |
20.2 |
22.6 |
24.3 |
25.8 |
||
Average Number of Shares Outstanding (m) |
297.5 |
298.9 |
299.7 |
303.1 |
304.7 |
305.9 |
305.9 |
||
EPS - normalised (p) - Edison |
|
|
3.84 |
5.70 |
6.52 |
6.82 |
7.68 |
8.12 |
8.60 |
EPS - normalised (p) |
|
|
3.67 |
5.53 |
6.35 |
6.65 |
7.51 |
7.96 |
8.43 |
EPS - statutory (p) |
|
|
2.89 |
5.13 |
6.02 |
6.65 |
7.43 |
7.96 |
8.43 |
Dividend per share (p) |
1.5 |
2.3 |
4.3 |
2.8 |
3.0 |
3.3 |
3.6 |
||
Gross Margin (%) |
8.3 |
9.9 |
10.7 |
11.0 |
11.9 |
11.9 |
12.0 |
||
EBITDA Margin (%) |
7.9 |
9.8 |
10.6 |
10.6 |
11.4 |
11.6 |
11.8 |
||
Operating Margin - Edison (%) |
6.4 |
8.4 |
9.2 |
9.2 |
9.9 |
10.0 |
10.1 |
||
BALANCE SHEET |
|||||||||
Fixed Assets |
|
|
149.3 |
148.3 |
154.5 |
163.0 |
185.9 |
197.2 |
202.0 |
Intangible Assets |
59.2 |
56.3 |
54.8 |
54.7 |
69.7 |
76.7 |
76.7 |
||
Tangible Assets |
77.4 |
78.9 |
81.2 |
84.0 |
90.2 |
92.7 |
94.8 |
||
Investments |
12.7 |
13.1 |
18.5 |
24.3 |
26.0 |
27.8 |
30.5 |
||
Current Assets |
|
|
75.1 |
107.1 |
99.2 |
91.8 |
101.1 |
108.5 |
121.0 |
Stocks |
5.3 |
7.8 |
9.6 |
8.9 |
9.8 |
11.4 |
12.5 |
||
Debtors |
50.7 |
66.5 |
56.4 |
57.7 |
64.3 |
70.3 |
73.8 |
||
Cash |
19.0 |
32.8 |
33.1 |
25.2 |
27.1 |
26.9 |
34.7 |
||
Current Liabilities |
|
|
(58.2) |
(78.7) |
(66.1) |
(58.6) |
(62.9) |
(66.7) |
(68.5) |
Creditors |
(58.1) |
(78.5) |
(65.9) |
(58.6) |
(62.9) |
(66.6) |
(68.4) |
||
Short term borrowings |
(0.2) |
(0.2) |
(0.2) |
(0.0) |
(0.0) |
(0.0) |
(0.0) |
||
Long Term Liabilities |
|
|
(17.9) |
(22.5) |
(18.7) |
(21.2) |
(35.2) |
(35.2) |
(35.2) |
Long term borrowings |
(0.4) |
(0.2) |
(0.0) |
0.0 |
(14.0) |
(14.0) |
(14.0) |
||
Other long term liabilities |
(17.5) |
(22.3) |
(18.6) |
(21.2) |
(21.2) |
(21.2) |
(21.2) |
||
Net Assets |
|
|
148.2 |
154.2 |
169.0 |
175.0 |
188.9 |
204.0 |
219.4 |
CASH FLOW |
|||||||||
Operating Cash Flow |
|
|
24.8 |
27.4 |
22.9 |
18.0 |
29.1 |
29.8 |
32.2 |
Net Interest |
(0.2) |
(0.1) |
(0.2) |
(0.4) |
(0.2) |
(0.6) |
(0.6) |
||
Tax |
(0.9) |
(2.4) |
(3.9) |
(3.4) |
(6.2) |
(5.0) |
(5.4) |
||
Capex |
(4.3) |
(5.3) |
(5.4) |
(6.3) |
(7.5) |
(7.5) |
(7.5) |
||
Acquisitions/disposals |
(4.1) |
(0.4) |
(5.5) |
(4.2) |
(18.5) |
(7.5) |
(0.5) |
||
Financing |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
||
Dividends |
(3.0) |
(5.1) |
(7.5) |
(13.4) |
(8.7) |
(9.3) |
(10.4) |
||
Net Cash Flow |
12.4 |
14.0 |
0.4 |
(8.0) |
(12.1) |
(0.1) |
7.9 |
||
Opening net debt/(cash) |
|
|
(6.1) |
(18.4) |
(32.4) |
(32.9) |
(25.2) |
(13.0) |
(12.8) |
HP finance leases |
(0.2) |
(0.2) |
(0.2) |
(0.2) |
0.0 |
0.0 |
0.0 |
||
Other |
0.2 |
0 |
0 |
0 |
(0) |
(0) |
(0) |
||
Closing net debt/(cash) |
|
|
(18.4) |
(32.4) |
(32.9) |
(25.2) |
(13.0) |
(12.8) |
(20.6) |
Source: Company accounts, Edison Investment Research
|
|
Research: Healthcare
At the 2019 European Society for Medical Oncology (ESMO) conference, Transgene presented the first efficacy data for TG4001 in combination with avelumab (Bavencio) in patients with human papillomavirus (HPV) positive cancers. In the Phase I trial, three out of nine patients treated demonstrated a durable partial response, and no dose-limiting toxicities were observed among the nine patients. All patients had metastatic disease and had previously undergone multiple lines of therapy. The tumour types selected have historically demonstrated low response rates to immune checkpoint inhibitors and we view this early data as positive for TG4001. We retain our valuation of Transgene at €287m (€3.45/share).